Cargando…
Muscle Mass and Inflammation in Older Adults: Impact of the Metabolic Syndrome
BACKGROUND: Inflammatory processes are a cause of accelerated loss of muscle mass. Metabolic syndrome (MetS) is a highly prevalent age-related condition, which may promote and be promoted by inflammation. However, whether inflammation in MetS (metaflammation) is associated with lower muscle mass is...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501741/ https://www.ncbi.nlm.nih.gov/pubmed/35100595 http://dx.doi.org/10.1159/000520096 |
_version_ | 1784795546458783744 |
---|---|
author | Buchmann, Nikolaus Fielitz, Jens Spira, Dominik König, Maximilian Norman, Kristina Pawelec, Graham Goldeck, David Demuth, Ilja Steinhagen-Thiessen, Elisabeth |
author_facet | Buchmann, Nikolaus Fielitz, Jens Spira, Dominik König, Maximilian Norman, Kristina Pawelec, Graham Goldeck, David Demuth, Ilja Steinhagen-Thiessen, Elisabeth |
author_sort | Buchmann, Nikolaus |
collection | PubMed |
description | BACKGROUND: Inflammatory processes are a cause of accelerated loss of muscle mass. Metabolic syndrome (MetS) is a highly prevalent age-related condition, which may promote and be promoted by inflammation. However, whether inflammation in MetS (metaflammation) is associated with lower muscle mass is still unclear. METHODS: Complete cross-sectional data on body composition, MetS, and the inflammatory markers interleukin (IL)-1β, IL-6, IL-10, tumor necrosis factor (TNF), and C-reactive protein (CRP) were available for 1,377 BASE-II participants (51.1% women; 68 ± 4 years old). Appendicular lean mass (ALM) was assessed by dual-energy X-ray absorptiometry. Low muscle mass (low ALM-to-BMI ratio [ALMBMI]) was defined according to the Foundation for the National Institutes of Health (FNIH) Sarcopenia Project. Regression models, adjusted for an increasing number of confounders (sex, age, physical activity, morbidities, diabetes mellitus type II, TSH, albumin, HbA1c, smoking habits, alcohol intake, education, and energy intake/day), were used to calculate the association between low ALMBMI and high inflammation (tertile 3) according to MetS. RESULTS: MetS was present in 36.2% of the study population, and 9% had low ALMBMI. In the whole study population, high CRP (odds ratio [OR]: 2.7 [95% CI: 1.6–4.7; p = 0.001]) and high IL-6 (OR: 2.1 [95% CI: 1.2–1.9; p = 0.005]) were associated with low ALMBMI. In contrast, no significant association was found between TNF, IL-10, or IL-1β with low ALMBMI. When participants were stratified by MetS, results for IL-6 remained significant only in participants with MetS. CONCLUSIONS: Among BASE-II participants, low ALMBMI was associated with inflammation. Low-grade inflammation triggered by disease state, especially in the context of MetS, might favor loss of muscle mass, so a better control of MetS might help to prevent sarcopenia. Intervention studies to test whether strategies to prevent MetS might also prevent loss of muscle mass seem to be promising. |
format | Online Article Text |
id | pubmed-9501741 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-95017412022-09-24 Muscle Mass and Inflammation in Older Adults: Impact of the Metabolic Syndrome Buchmann, Nikolaus Fielitz, Jens Spira, Dominik König, Maximilian Norman, Kristina Pawelec, Graham Goldeck, David Demuth, Ilja Steinhagen-Thiessen, Elisabeth Gerontology Clinical Section: Research Article BACKGROUND: Inflammatory processes are a cause of accelerated loss of muscle mass. Metabolic syndrome (MetS) is a highly prevalent age-related condition, which may promote and be promoted by inflammation. However, whether inflammation in MetS (metaflammation) is associated with lower muscle mass is still unclear. METHODS: Complete cross-sectional data on body composition, MetS, and the inflammatory markers interleukin (IL)-1β, IL-6, IL-10, tumor necrosis factor (TNF), and C-reactive protein (CRP) were available for 1,377 BASE-II participants (51.1% women; 68 ± 4 years old). Appendicular lean mass (ALM) was assessed by dual-energy X-ray absorptiometry. Low muscle mass (low ALM-to-BMI ratio [ALMBMI]) was defined according to the Foundation for the National Institutes of Health (FNIH) Sarcopenia Project. Regression models, adjusted for an increasing number of confounders (sex, age, physical activity, morbidities, diabetes mellitus type II, TSH, albumin, HbA1c, smoking habits, alcohol intake, education, and energy intake/day), were used to calculate the association between low ALMBMI and high inflammation (tertile 3) according to MetS. RESULTS: MetS was present in 36.2% of the study population, and 9% had low ALMBMI. In the whole study population, high CRP (odds ratio [OR]: 2.7 [95% CI: 1.6–4.7; p = 0.001]) and high IL-6 (OR: 2.1 [95% CI: 1.2–1.9; p = 0.005]) were associated with low ALMBMI. In contrast, no significant association was found between TNF, IL-10, or IL-1β with low ALMBMI. When participants were stratified by MetS, results for IL-6 remained significant only in participants with MetS. CONCLUSIONS: Among BASE-II participants, low ALMBMI was associated with inflammation. Low-grade inflammation triggered by disease state, especially in the context of MetS, might favor loss of muscle mass, so a better control of MetS might help to prevent sarcopenia. Intervention studies to test whether strategies to prevent MetS might also prevent loss of muscle mass seem to be promising. S. Karger AG 2022-09 2022-01-31 /pmc/articles/PMC9501741/ /pubmed/35100595 http://dx.doi.org/10.1159/000520096 Text en Copyright © 2022 by The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by/4.0/This article is licensed under the Creative Commons Attribution 4.0 International License (CC BY). Usage, derivative works and distribution are permitted provided that proper credit is given to the author and the original publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. |
spellingShingle | Clinical Section: Research Article Buchmann, Nikolaus Fielitz, Jens Spira, Dominik König, Maximilian Norman, Kristina Pawelec, Graham Goldeck, David Demuth, Ilja Steinhagen-Thiessen, Elisabeth Muscle Mass and Inflammation in Older Adults: Impact of the Metabolic Syndrome |
title | Muscle Mass and Inflammation in Older Adults: Impact of the Metabolic Syndrome |
title_full | Muscle Mass and Inflammation in Older Adults: Impact of the Metabolic Syndrome |
title_fullStr | Muscle Mass and Inflammation in Older Adults: Impact of the Metabolic Syndrome |
title_full_unstemmed | Muscle Mass and Inflammation in Older Adults: Impact of the Metabolic Syndrome |
title_short | Muscle Mass and Inflammation in Older Adults: Impact of the Metabolic Syndrome |
title_sort | muscle mass and inflammation in older adults: impact of the metabolic syndrome |
topic | Clinical Section: Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501741/ https://www.ncbi.nlm.nih.gov/pubmed/35100595 http://dx.doi.org/10.1159/000520096 |
work_keys_str_mv | AT buchmannnikolaus musclemassandinflammationinolderadultsimpactofthemetabolicsyndrome AT fielitzjens musclemassandinflammationinolderadultsimpactofthemetabolicsyndrome AT spiradominik musclemassandinflammationinolderadultsimpactofthemetabolicsyndrome AT konigmaximilian musclemassandinflammationinolderadultsimpactofthemetabolicsyndrome AT normankristina musclemassandinflammationinolderadultsimpactofthemetabolicsyndrome AT pawelecgraham musclemassandinflammationinolderadultsimpactofthemetabolicsyndrome AT goldeckdavid musclemassandinflammationinolderadultsimpactofthemetabolicsyndrome AT demuthilja musclemassandinflammationinolderadultsimpactofthemetabolicsyndrome AT steinhagenthiessenelisabeth musclemassandinflammationinolderadultsimpactofthemetabolicsyndrome |